氯雷他定和苯磺贝他斯汀治疗过敏性鼻炎的临床效果评价

Abstract
Figure/Table
References (15)
Related Citation (9)

Download: PDF (0 KB) HTML (41 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To discuss the clinical treatment effect of loratadine and phenylsulfonic bepotastine besilate in the treatment of rhinallergosis.Methods Ninety-eight cases of patients with rhinallergosis in our hospital from March 2014 to April 2016 were selected and divided into group A and group B according to the time of admission.The group A were treated with loratadine，while the group B were treated with phenylsulfonic bepotastine besilate.The levels of IgE and ECP，clinical signs and symptoms，adverse reactions and VAS scores in the two groupswere observed and compared，then the clinical treatment effect was compared in the two groups.Results The total effective rate in the group B was significantly higher than that in the group A，the difference was statistically significant（P＜0.01）.After treatment，The levels of IgE and ECP in the group B was obviously lower than that in the group A respectively，with significant differences （P＜0.01）.The scores of clinical signs and symptoms in the group B was obviously lower than that in the group A respectively with significant differences（P＜0.01）.After treatment，the VAS scores of two groupswas significantly lower and the VAS score of group B was lower than that of group A，the difference was statistically significant（P＜0.01），the incidence rate of adverse reactions of group B was significantly lower than that in the group A，and the differenceswere statistically significant（P＜0.05）.Conclusion The clinical treatment effect of phenylsulfonic bepotastine besilate in the treatment of rhinallergosis is better than that of loratadine，which isworthy promotion in clinic.

Key words： Loratadine Phenylsulfonic bepotastine besilate Rhinallergosis Immunoglobulin Eosinophil cationic protein

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	HUANG He
	LIMan-lan
	WANG Dong-yan
	ZHANGGui-yang
	ZHANG Han-wen

Cite this article:

HUANG He,LIMan-lan,WANG Dong-yan, et al. Evaluation of clinical effect of loratadine and phenylsulfonic bepotastine besilate in the treatment of rhinallergosis[J]. 中国当代医药, 2016, 23(26): 89-92.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2016/V23/I26/89

［1］	罗勇.试论过敏性鼻炎患者的临床治疗体会［J］.中国实用医药，2016，11（5）：185-186.
［2］	崔林晖.嗜酸性粒细胞增多综合征2例并文献复习［D］.大连：大连医科大学，2014.
［3］	中华医学会耳鼻喉科分会，中华耳鼻喉科杂志编辑委员会.变应性鼻炎诊断和疗效评定标准［J］.中华耳鼻咽喉科杂志，1991，26（3）：134.
［4］	焦雪芹，张志永.过敏性鼻炎评分量表（SFAR）与临床病程相关性研究［J］.中国现代医生，2014，52（14）：136-137，140. ［5］Patro SK，Verma RK，Panda NK，et al.Understanding paediatric allergic fungal sinusitis：is itmore aggressive？［J］.Int J Pediatr Otorhinolaryngol，2015，79（11）：1876-1880.
［6］	严广斌.视觉模拟评分法［J］.中华关节外科杂志（电子版），2014，9（2）：273.
［7］	罗红强，罗兴中.过敏性鼻结膜炎治疗的研究现状［J］.江西医药，2016，51（5）：483-486.
［8］	张伟，赵岩，王成硕，等.过敏性鼻炎患者伴发食物过敏原致敏状态分析［J］.首都医科大学学报，2011，32（1）：8-12.
［9］	Price DB，Scadding　G，Bachert C，et al.UK　prescribing practices as proxy markers of unmet need in allergic rhinitis：a retrospective observational study［J］.NPJ Prim Care Respir Med，2016，13（26）：16033.
［10］	尤少华.变应性鼻炎特异性免疫治疗的疗效和安全性研究［D］.北京：解放军医学院，2014.
［11］	李宏，顾建青，张罗，等.苯磺贝他斯汀与氯雷他定治疗过敏性鼻炎：多中心随机双盲临床试验［J］.中华临床免疫和变态反应杂志，2013，7（1）：45-50.
［12］	黄员福，薛梅，欧锦添.氯雷他定联合布地奈德鼻喷剂治疗过敏性鼻炎的效果观察［J］.中国当代医药，2015，22（35）：148-150.
［13］	梁亚涛.氯雷他定衍生物的合成及其药物有效性、安全性评价研究［D］.天津：天津大学，2013.
［14］	张燕，毛增宇，张媛.苯磺贝他斯汀治疗过敏性鼻炎的有效性和安全性分析［J］.中国医药导报，2013，10（26）：85-86，89.
［15］	闫雅茹，王怡玮，王菁兰，等.变应性鼻炎伴哮喘患者特异性免疫治疗速发型不良反应的观察［J］.现代免疫学，2016，36（1）：46-49.